This study showed some evidence of an effect of Zn alone or in combination with Se on thyroid function of overweight or obese female hypothyroid patients.

No abstract

Purpose: To evaluate the effect of cabergoline treatment on metabolic parameters including the Triglyceride-glucose (TyG) index in newly diagnosed patients with prolactinoma.Methods: 71 consecutive non-diabetic patients with prolactinoma were enrolled. Body mass index (BMI), blood pressure, and laboratory tests including TyG index were measured for each patient. Then, treatment with cabergoline was started for each patient and continued for 6 months. Anthropometric and laboratory tests were repeated every 3 months to evaluate the effects of cabergoline treatment.Results: At the baseline examination, the mean (SD) age, BMI, waist circumference (WC), systolic blood pressure (SBP), and diastolic blood pressure (DBP) of patients were 36.2 (10.5) years, 29.2 (5.0) kg/m 2 , 98.2 (13.7) cm, 115.3 (13.3) mmHg, and 71.4 (8.1) mmHg, respectively. Furthermore, men were older and had higher values for BMI, WC, SBP, and metabolic syndrome (MetS) prevalence compared to women. Cabergoline treatment signi cantly improved anthropometric and metabolic measures including BMI, WC, fasting plasma glucose, triglycerides, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, uric acid (only among women), TyG index, and hypogonadism, while no signi cant change was detected in SBP and DBP. No signi cant change was found in Mets syndrome prevalence among women whereas the declining trend from baseline to 3-month evaluation was signi cant among men.Conclusion: Short-term treatment with cabergoline can signi cantly improve cardiovascular risk factors except for blood pressure. Moreover, the TyG index as a surrogate marker of insulin resistance decreased signi cantly after the reduction of prolactin by treatment. Generally, results were similar among both genders.

Objective: This study aimed to explore the scientific performance in research of endocrinology and metabolism and its correlation with the socioeconomic indicators in the Middle-East countries. Material and Methods: Scientometrics and social network analysis methods were used for this study. Data were extracted from the Web of Science, World Bank, and UIS data center of UNESCO. Results: The majority of scientific productions (79.6%) were published by authors affiliated with upper-middle and high income countries which includes Turkey, Israel, and Iran. From co-authorship analysis, Saudi Arabia, Egypt, and Turkey with most degree centrality, had the highest collaborative ranking with other Middle-East countries. The main Middle-East collaborators having scientific outputs in this field were the researchers from the USA, England, and Germany. Israel, Turkey, and Saudi Arabia had the most collaboration (63.8%) with other countries. Also, there was a strong positive correlation between total collaborations with global countries and the number of citations. Conclusion: Due to the correlation among scientific productions, citations, scientific collaborations, Gross domestic expenditure on research and development, and specialist human resources indicators, the supplementary budget should be directed toward research in the Middle-East countries and establishing global networks to conduct joint projects. This could increase the trend of scientific productions and obtain higher citations in the Web of Science, eventually leading to scientific, social as well as economic development in the region.

Purpose: To evaluate the effect of cabergoline treatment on metabolic parameters including the Triglyceride-glucose (TyG) index in newly diagnosed patients with prolactinoma.Methods: 71 consecutive non-diabetic patients with prolactinoma were enrolled. Body mass index (BMI), blood pressure, and laboratory tests including TyG index were measured for each patient. Then, treatment with cabergoline was started for each patient and continued for 6 months. Anthropometric and laboratory tests were repeated every 3 months to evaluate the effects of cabergoline treatment. Results: At the baseline examination, the mean (SD) age, BMI, waist circumference (WC), systolic blood pressure (SBP), and diastolic blood pressure (DBP) of patients were 36.2 (10.5) years, 29.2 (5.0) kg/m2, 98.2 (13.7) cm, 115.3 (13.3) mmHg, and 71.4 (8.1) mmHg, respectively. Furthermore, men were older and had higher values for BMI, WC, SBP, and metabolic syndrome (MetS) prevalence compared to women. Cabergoline treatment significantly improved anthropometric and metabolic measures including BMI, WC, fasting plasma glucose, triglycerides, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, uric acid (only among women), TyG index, and hypogonadism, while no significant change was detected in SBP and DBP. No significant change was found in Mets syndrome prevalence among women whereas the declining trend from baseline to 3-month evaluation was significant among men. Conclusion: Short-term treatment with cabergoline can significantly improve cardiovascular risk factors except for blood pressure. Moreover, the TyG index as a surrogate marker of insulin resistance decreased significantly after the reduction of prolactin by treatment. Generally, results were similar among both genders.